- Home
- LPTX vs OFS Comparison
LPTX vs OFS Comparison
Compare LPTX & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- OFS
- Stock Information
- Founded
- LPTX 2011
- OFS 2001
- Country
- LPTX United States
- OFS United States
- Employees
- LPTX N/A
- OFS N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- OFS Finance/Investors Services
- Sector
- LPTX Health Care
- OFS Finance
- Exchange
- LPTX Nasdaq
- OFS Nasdaq
- Market Cap
- LPTX 119.6M
- OFS 120.2M
- IPO Year
- LPTX N/A
- OFS 2012
- Fundamental
- Price
- LPTX $0.33
- OFS $8.56
- Analyst Decision
- LPTX Hold
- OFS
- Analyst Count
- LPTX 1
- OFS 0
- Target Price
- LPTX N/A
- OFS N/A
- AVG Volume (30 Days)
- LPTX 3.3M
- OFS 66.5K
- Earning Date
- LPTX 08-11-2025
- OFS 07-31-2025
- Dividend Yield
- LPTX N/A
- OFS 15.85%
- EPS Growth
- LPTX N/A
- OFS N/A
- EPS
- LPTX N/A
- OFS 2.25
- Revenue
- LPTX N/A
- OFS $44,026,000.00
- Revenue This Year
- LPTX N/A
- OFS N/A
- Revenue Next Year
- LPTX N/A
- OFS N/A
- P/E Ratio
- LPTX N/A
- OFS $3.81
- Revenue Growth
- LPTX N/A
- OFS N/A
- 52 Week Low
- LPTX $0.22
- OFS $7.75
- 52 Week High
- LPTX $4.79
- OFS $9.80
- Technical
- Relative Strength Index (RSI)
- LPTX 48.69
- OFS 45.54
- Support Level
- LPTX $0.28
- OFS $8.42
- Resistance Level
- LPTX $0.36
- OFS $8.69
- Average True Range (ATR)
- LPTX 0.04
- OFS 0.26
- MACD
- LPTX 0.01
- OFS -0.01
- Stochastic Oscillator
- LPTX 39.43
- OFS 21.92
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.